BCMA chimeric antigen receptor T cells therapy re-treatment of a patient with recurrent/refractory IgD multiple myeloma: A case report and literature review
10.3760/cma.j.cn121090-20240426-00165
- VernacularTitle:IgD型复发难治多发性骨髓瘤患者BCMA靶点再治疗1例报告并文献复习
- Author:
Sinan GU
1
;
Wanting QIANG
;
Jing LU
;
Zhongyuan FENG
;
Juan DU
Author Information
1. 海军军医大学第二附属医院（上海长征医院）血液病科，全军骨髓瘤与淋巴瘤疾病中心，上海 200003
- From:
Chinese Journal of Hematology
2024;45(10):951-955
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma (MM) is a malignant plasma cell disease that currently cannot be cured. Several new drugs have continuously been introduced in the recent years. New drugs targeting B-cell maturation antigen (BCMA) have greatly improved the efficacy and prognosis of MM compared with traditional treatments. This article reports the case of an IgD type relapsed and refractory MM patient with poor efficacy of BCMA×CD3 bispecific antibody. The patient achieved deep remission after receiving BCMA-targeted CAR-T cell therapy after initial seven lines of treatment. Literature review was also conducted to improve the clinical physicians’ understanding of BCMA target therapy for relapsed and refractory MM patients.
